Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 11Carcinoma, Hepatocellular 7Colorectal Neoplasms 5Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumor 4Solid Tumor 3Small Cell Lung Carcinoma 3Esophageal Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Melanoma 2Lung Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumour 2Unresectable Stage III Non-small Cell Lung Cancer 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Simpson-Golabi-Behmel syndrome 1Rectal Neoplasms 1Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1Metastatic Solid Tumors 1MSI-H/dMMR Solid Tumors 1

Interventions

Injections 4tislelizumab 2Paclitaxel 2Cisplatin 2Capecitabine 2Bevacizumab 2Pemetrexed 1Oxaliplatin 1Gemcitabine 1Fluorouracil 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Solid Tumour × tislelizumab × 90 days × Clear all
NCT07331155 2026-05-18

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Nanjing Leads Biolabs Co.,Ltd

Phase 2 Recruiting
110 enrolled
Other solid neoplasm

Advanced Solid Tumour

NCT07390383 2026-05-13

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Nanjing Leads Biolabs Co.,Ltd

Phase 2 Recruiting
110 enrolled
Other solid neoplasm

Advanced Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡